CTGF as a multifunctional molecule for cartilage and a potential drug for osteoarthritis

Zihuan Yang1, Weishi Li1,2, Chunli Song1,3

  • 1Department of Orthopaedics, Peking University Third Hospital, Beijing, China.

Insights

Connective tissue growth factor (CTGF) plays a key role in joint homeostasis. Targeting CTGF with antibodies, like pamrevlumab, shows promise for treating osteoarthritis by preventing cartilage degeneration and fibrosis.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Rheumatology

Background:

  • Connective tissue growth factor (CTGF) is a multifunctional protein involved in various cellular processes.
  • Elevated CTGF expression is observed in osteoarthritis (OA) joints compared to healthy joints.
  • CTGF is crucial for chondrocyte function and maintaining joint homeostasis.

Purpose of the Study:

  • To review the physiological functions of CTGF in chondrocytes.
  • To discuss the mechanisms underlying abnormal CTGF expression in OA.
  • To evaluate CTGF as a potential therapeutic target for osteoarthritis.

Main Methods:

  • Literature review of studies on CTGF in chondrocytes and OA.
  • Analysis of signaling pathways affected by abnormal CTGF expression.
  • Examination of existing data on CTGF-targeting therapies.

Main Results:

  • Abnormal CTGF expression contributes to cartilage degeneration, inflammation, and synovial fibrosis in OA.
  • CTGF is essential for normal chondrocyte function and joint homeostasis.
  • CTGF antibodies, such as pamrevlumab, are being investigated for OA treatment.

Conclusions:

  • CTGF plays a significant role in the pathogenesis of osteoarthritis.
  • Modulating CTGF activity presents a potential therapeutic strategy for OA.
  • Further research into CTGF-targeting therapies could lead to novel treatments for OA.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K
Glycosaminoglycans01:23

Glycosaminoglycans

Glycosaminoglycans (GAGs), also known as mucopolysaccharides, are long and linear polymers comprising of specific repeating disaccharides - the amino sugar that can be N-acetylglucosamine or N-acetylgalactosamine, and a uronic acid that is usually glucuronic acid or iduronic acid.
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
5.0K
Growth of Cartilage and Bone Tissue01:27

Growth of Cartilage and Bone Tissue

Chondrocytes form a temporary cartilaginous model by dividing and secreting a thick gel-like extracellular matrix. Once the chondrocytes undergo programmed cell death, osteoblasts enter the site of the cartilaginous model. The process of replacing the temporary cartilaginous model with bone in an ordered manner is called endochondral ossification. In endochondral ossification, not all of the cartilage is replaced by bone tissue. Some cartilage that performs a protective and supportive function...
3.4K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.1K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
188
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
249